AI drug discovery is entering a more demanding phase.
For several years, the industry was evaluated through model performance, funding rounds and large partnership announcements. In 2026, the standard is moving closer to clinical evidence: Can an AI-enabled platform repeatedly produce candidates that survive development and help patients?
This watchlist considers four public signals:
- Clinical progress
- Pharmaceutical partnerships
- Platform expansion
- Financing that can support pipeline development
The companies are numbered for readability rather than ranked from strongest to weakest.
1. Insilico Medicine
Insilico has moved further into clinical development than most companies identified with generative AI drug discovery.
In September 2026, the company announced that the first patient had been dosed in a Phase III study of rentosertib for idiopathic pulmonary fibrosis. That makes Insilico particularly important to watch as the industry looks for evidence that AI-discovered targets and molecules can produce meaningful clinical results. Insilico Medicine announcement
Signal to watch: Phase III execution, clinical outcomes and whether its partnership model can produce additional development candidates.
2. Recursion
Recursion combines large-scale biological data generation, machine learning and an internal and partnered therapeutic pipeline.
Its February 2026 update reported clinical validation in familial adenomatous polyposis, five accepted Sanofi discovery packages and $134 million in payments from the collaboration. The company has also continued its neuroscience work with Roche and Genentech. Recursion 2026 business update
Signal to watch: Whether its operating system can repeatedly translate biological maps into differentiated clinical programs.
3. Generate:Biomedicines
Generate applies generative biology to protein therapeutics rather than concentrating only on small molecules.
Its AI-engineered anti-TSLP antibody, GB-0895, is moving toward global Phase III studies for severe asthma. Generate also completed an IPO in February 2026, giving the company another source of capital for clinical development. Generate:Biomedicines news releases
Signal to watch: Late-stage validation of an AI-engineered biologic and the expansion of its generative protein platform into additional modalities.
4. Iambic Therapeutics
Iambic has combined internal clinical programs with a rapidly expanding group of pharmaceutical partnerships.
In October, it submitted an IND for IAM217, which the company describes as its second wholly owned AI-discovered candidate. Its 2026 announcements also include collaborations with Takeda, Bayer and AbbVie. Iambic news and announcements
Signal to watch: Progress of its internal oncology pipeline and whether its platform can perform consistently across multiple partner programs.
5. Isomorphic Labs
Isomorphic Labs remains one of the best-capitalized companies in AI drug design.
In May 2026, the company announced a $2.1 billion Series B financing to scale its IsoDDE drug-design engine and move therapeutic programs toward the clinic. Its next test will be translating sophisticated predictive models into development-ready candidates. Isomorphic Labs funding announcement
Signal to watch: The first clinical programs emerging from its internal pipeline and collaborations.
6. insitro
insitro is building a broader platform that connects causal biology, human data and therapeutic design.
The acquisition of CombinAbleAI expanded its TherML platform across small molecules, oligonucleotides and biologics. In 2026, insitro also expanded its ALS work with Bristol Myers Squibb and introduced an in-vivo pharmacokinetic model developed with Lilly data. TherML announcement Lilly PK model
Signal to watch: Whether a cross-modality platform improves target selection and candidate quality before clinical testing.
7. Genesis Molecular AI
Genesis focuses on foundation models and physics-informed molecular design for small-molecule discovery.
In May 2026, Incyte expanded its collaboration with Genesis. The agreement included $120 million in upfront consideration and equity investment, with additional development, regulatory and commercial milestones possible. Incyte and Genesis announcement
Signal to watch: How effectively proprietary pharmaceutical data improves the GEMS platform and produces validated molecules.
8. Owkin
Owkin is combining multimodal patient data, biological models, drug discovery and AI agents.
Its 2026 announcements include AI-agent work with AstraZeneca and Sanofi, as well as clinical development activity around its oncology program OKN4395. Owkin news center
Signal to watch: Whether Owkin can connect patient-derived biological insight with target selection, biomarkers and clinical development.
9. Profluent
Profluent applies generative AI to protein design and gene-editing systems.
The company announced a strategic partnership with Lilly to develop AI-designed recombinases, with reported potential deal value of up to $2.25 billion. In September, it also announced a BioMarin partnership involving AI-designed medicines. Profluent media center
Signal to watch: Translation of AI-authored proteins and gene editors into therapeutic programs with sufficient efficacy, specificity and developability.
10. Xaira Therapeutics
Xaira entered the field with substantial funding and a team spanning machine learning, biological research and drug development.
In October 2026, the company provided an early look at its de novo antibody-design platform and emerging pipeline, including work on drug-like antibody leads and difficult targets. Xaira news and insights
Signal to watch: Whether its antibody platform can progress from designed binders to development-quality therapeutic candidates.
What the 2026 Watchlist Signals
Three themes stand out.
First, clinical evidence is becoming the real dividing line. Platform demonstrations remain valuable, but human data will determine which approaches create durable value.
Second, pharma companies are providing proprietary data as well as capital. Several collaborations now involve training models on experimental datasets that are difficult to reproduce outside established R&D organizations.
Third, AI drug discovery is expanding across modalities. The field now includes small molecules, antibodies, proteins, oligonucleotides, recombinases and gene-editing systems.
Large deal values require careful interpretation. Published totals often include contingent development, regulatory and commercial milestones. They are neither guaranteed payments nor evidence that a program will succeed.
For job seekers, the companies are also worth watching for the combination of disciplines they require: machine learning, computational chemistry, data engineering, laboratory automation, medicinal chemistry, translational biology, clinical development and program management.
Explore AI and biotechnology openings on GetBioJob, compare the scientific platforms behind each employer, and evaluate the work rather than relying on the “AI biotech” label alone.